- Home
- ATER vs GTBP Comparison
ATER vs GTBP Comparison
Compare ATER & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATER | GTBP |
|---|---|---|
| Founded | 2014 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3M | 8.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ATER | GTBP |
|---|---|---|
| Price | $0.83 | $0.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 193.8K | ★ 2.0M |
| Earning Date | 11-13-2025 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $78,450,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $0.54 |
| 52 Week High | $3.50 | $3.85 |
Technical Indicators
Market Signals| Indicator | ATER | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 56.15 | 42.16 |
| Support Level | $0.64 | $0.76 |
| Resistance Level | $0.82 | $0.87 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 64.26 | 2.58 |
Price Performance
Historical ComparisonAbout ATER Aterian Inc.
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operates brands, including HomeLabs, Squatty Potty, Healing Solutions, PurSteam, and others. The company generates revenue through the online sales of various consumer products that are sold online.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.